 |
Prospector
Profile
08.0008
|
| |
| ChemGenex Pharmaceuticals Ltd. |
NAICS |
541710 |
| P.O. Box 1069
Grovedale, Victoria, Australia 3216 |
Description |
Biotechnology |
| 011-613-5227-2752 |
Employees |
8 |
| http://www.chemgenex.com/wt/home/index |
Revenue |
(mil) |
1.3980 |
| |
Income |
(mil) |
-11.7000 |
| |
Assets |
(mil) |
42.7610 |
| |
Liability |
(mil) |
2.8910 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
ChemGenex Pharmaceuticals Ltd. had a net loss of $11,379,415 for the year ended June 30, 2007, which is higher than the net losses of $10,369,719 and $6,235,183 during the years ended June 30, 2006 and 2005, respectively. The Company reported total revenue of $1,398,207 for the year ended June 30, 2007, much lower than the revenue of $1,917,931 and $3,794,299 reported during the previous fiscal years. As a result of its recurring losses, the Company's balance sheet at June 30, 2007, showed an accumulated deficit of $92,723,921.
|
| |
|
Intellectual Property:
The Company’s success depends on its ability to obtain and maintain protection for its inventions and proprietary information. The Company also relies on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation, which are protected with security measures, including confidentiality agreements with collaborators, consultants and employees. The Company owns a portfolio of patents and patent applications, including 22 PCT applications. Currently derived from these applications are over 96 national and regional patent applications in 12 different jurisdictions, including the U.S., Europe and Japan. The portfolio also includes 20 provisional patent applications that have been submitted in the past year. [SEC Filing 20-F 11-27-07]
|
| |
|
Description:
The Company develops targeted medicines for the treatment of cancer, diabetes and obesity.
|
| |
|
Officers:
Brett Heading (Chair); Greg Collier (CEO & Managing Dir.); Dennis Brown (Pres. & Dir.); Adam R. Craig (SVP & Chief Medical Officer); Rick Merrigan (Sec. & CFO); James Campbell (VP); Ian Nisbet (VP)
|
| |
|
Auditor:
Ernst & Young
|
| |
|
Securities:
Common Stock-Symbol CXSP; Nasdaq;
185,847,331 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
